Zentrogene Laboratory, an international genetic testing institution based in Hong Kong, announced the launch of its ‘Y Precision’ testing technology based on Next-Generation Sequencing.
This locally developed innovation in Hong Kong addresses longstanding industry challenges in gender determination for twin pregnancies.
It overcomes the limitations of traditional qPCR platforms, achieving the first-ever precise identification of male-female twins while significantly enhancing the accuracy of fetal cell-free DNA (cfDNA) analysis.
Traditional methods could only qualitatively detect the presence of the Y chromosome, failing to distinguish between male-male twins and male-female twins. They also lacked the capability to identify residual male cfDNA after fetal reduction procedures.
Zentrogene’s NGS-based technology achieved three breakthroughs, including fetal signal assessment, using whole-genome SNP scanning to confirm fetal signal presence, precisely quantify fetal fraction, and determine the number of fetal signals; contamination identification that differentiates between false signals (e.g., contamination-derived Y chromosome fragments) and true fetal signals; and twin pregnancy precision analysis for independently analysing X and Y chromosome fragments to accurately distinguish male-female twins from male-male twins.
As a pioneer in Hong Kong’s genetic testing field, Zentrogene has established a global technology matrix covering pre-pregnancy, prenatal, and oncology applications through its integrated Sanger sequencing and NGS platforms.
This NGS breakthrough underscores its ‘Technology-Driven Globalisation’ strategy, leveraging Hong Kong’s expertise to deliver precision medical solutions worldwide. Zentrogene continues to advance genetic technology, safeguarding every family’s hopes with scientific rigour.
